Terms: = Brain cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Clinical Outcome
7 results:
1. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract] [Full Text] [Related]
2. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
[TBL] [Abstract] [Full Text] [Related]
3. Total copy number variation as a prognostic factor in adult astrocytoma subtypes.
Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE
Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992
[TBL] [Abstract] [Full Text] [Related]
4. p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.
Lummus SC; Donson AM; Gowan K; Jones KL; Vibhakar R; Foreman NK; Kleinschmidt-DeMasters BK
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28548702
[TBL] [Abstract] [Full Text] [Related]
5. Tracking the Evolution of Non-Small-Cell Lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
6. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract] [Full Text] [Related]
7. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract] [Full Text] [Related]
